Effect of semaglutide 2.4 mg on use of antihypertensive and lipid‐lowering treatment in five randomized controlled STEP trials

Documenti analoghi

• TOS / OMA / OAC Expert Guidance Statement on Obesity Pharmacotherapy: A Humbling Call to Action
  di: Beverly G. Tchang, et al.
  Pubblicazione: (2026)
• Efficacy and safety of once‐weekly semaglutide 2.4 mg for weight management in participants from China: A prespecified analysis of the STEP 7 randomized clinical trial
  di: Weijun Gu, et al.
  Pubblicazione: (2025)
• Effect of semaglutide 2.4 mg on physical functioning and weight‐ and health‐related quality of life in adults with overweight or obesity: Patient‐reported outcomes from the STEP 1–4 trials
  di: Domenica Rubino, et al.
  Pubblicazione: (2024)
• Tirzepatide 10 and 15 mg versus semaglutide 2.4 mg in people with obesity or overweight with type 2 diabetes: An indirect treatment comparison
  di: Emily R. Hankosky, et al.
  Pubblicazione: (2025)
• Treatment effect of semaglutide 2.4 mg on health‐related quality of life from STEP 1 SF‐6D derived from SF ‐36 with Australian weights
  di: Pavol Kral, et al.
  Pubblicazione: (2024)